President and CEOOfficers of the CorporationBoard of TrusteesLeadership CouncilHistory
Managing DiabetesChildhood DiabetesNutritionExerciseOnline Diabetes ClassesDiscussion BoardsInfo for Healthcare ProfessionalsJoslin Clinical Guidelines50-Year Medalist Program
Adult ClinicPediatricsEye CareBillingInfo for Healthcare ProfessionalsDiabetes Information & Resources
Clinical Research50-Year Medalist Study
Media RelationsNews ReleasesInside JoslinSocial Media
Affiliated CentersPharma & DeviceCorporate EducationPublicationsProfessional EducationInternational
Give NowGet InvolvedEventsTributes & Special OccasionsCorporate & Foundation EngagementLegacy GivingWays to GivePhilanthropy TeamPublications

Steven E. Shoelson, M.D., Ph.D.

Research Summary

Studies in the Shoelson lab focus on the pathogenesis of diabetes and its complications, and potential new avenues for treatment. More specifically, our lab focuses on potential roles of inflammation in the pathogenesis of diabetes (insulin resistance and β cell dysfunction) and its long term macrovascular (atherosclerosis) and microvascular (neuropathy, retinopathy, nephropathy) complications.  More than 10 years ago we rediscovered an arcane medical literature on the use of salicylate in diabetes, and have since developed this line of investigation to (1) better understand pathogenesis in insulin resistance, impaired β cell function, and T2D, (2) provide leads for pharmacological target identification and validation, and (3) develop potential new treatment strategies for patients with T2D and its microvascular complications. These studies led to our identifying both molecular (e.g. NF-κB) and cellular targets of salicylate, which include circulating monocytes and other elements of both innate and adaptive immune systems. These studies are of direct potential value to both researchers in the field and patients with cardiovascular disease and diabetes.

Page last updated: September 19, 2019